Press Releases

Date Title and Summary
Toggle Summary Ionis Presents New Data from NEURO-TTR Study and Highlights Programs from Its Neurological Disease Franchise at ANA Congress
Inotersen treatment resulted in a 20-point benefit in mNIS+7 compared to placebo Ionis antisense programs featured in 11 platform and poster presentations at ANA CARLSBAD, Calif. , Oct. 15, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today
Toggle Summary Ionis Pharmaceuticals Initiates Clinical Study of IONIS-MAPT Rx in Patients with Alzheimer's Disease
Antisense drug designed to reduce tau protein in the CNS Ionis earns $10 million milestone payment from Biogen CARLSBAD, Calif. , Oct. 13, 2017 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that it has initiated a Phase 1/2a clinical study of IONIS-MAPT Rx in patients
Toggle Summary Biogen’s SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with Spinal Muscular Atrophy
New data from Phase 3 ENDEAR study demonstrated earlier initiation of treatment with SPINRAZA may improve motor function outcomes in infants with Spinal Muscular Atrophy (SMA) Phase 2 EMBRACE interim analysis showed greater motor milestone achievement in infants and children treated with SPINRAZA,
Toggle Summary Akcea and Ionis Announce Filing of New Drug Submission for Volanesorsen to Health Canada
Health Canada grants priority review for volanesorsen NDS filing Volanesorsen could be the first approved treatment for patients with FCS CAMBRIDGE, Mass. and CARLSBAD, Calif., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc.
Toggle Summary New Data Presented at European Society for Medical Oncology Meeting Demonstrate Antitumor Activity with IONIS-STAT3-2.5 Rx in Combination with Imfinzi
29% Objective Response Rate and 57% Disease Control Rate in Combination with Immune Checkpoint Inhibitor Treatment in Patients with Head and Neck Cancer Four Complete Responses and Four Partial Responses Observed in 28-patient Study CARLSBAD, Calif. , Sept.
Toggle Summary Akcea and Ionis Announce Submission of New Drug Application for Volanesorsen to the U.S. FDA
<p>CAMBRIDGE, Mass., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today
Toggle Summary Ionis Earns $40 Million SPINRAZA Regulatory Milestone Payment from Biogen
CARLSBAD, Calif. , Aug. 30, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has earned a $40 million milestone payment from Biogen associated with the pricing approval of SPINRAZA ® (nusinersen) in Japan . SPINRAZA was approved for individuals with
Toggle Summary Ionis Recommends Shareholders Reject The Below-The-Market Mini-Tender Offer By TRC Capital Corporation
CARLSBAD, Calif. , Aug. 24, 2017 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Corporation of Ontario, Canada to purchase up to 2.5 million shares of Ionis' common stock at a price of $44.88
Toggle Summary Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif. , Aug. 17, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences: Southern California Investor Conference on Thursday, August 24,
Toggle Summary Ionis to Independently Advance Inotersen and IONIS-FB-L Rx
Inotersen on Track for Marketing Authorization Filings This Year Conference Call Webcast Friday, August 11, 8:30 a.m. ET at www.ionispharma.com CARLSBAD, Calif. , Aug. 11, 2017 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today reported that the Company has retained all rights to
Toggle Summary Akcea Reports Financial Results and Highlights for Second Quarter 2017
Toggle Summary Ionis Provides Improved 2017 Guidance Following Strong Financial Performance
Conference Call Webcast Tuesday, August 8, 11:30 a.m. ET at www.ionispharma.com CARLSBAD, Calif., Aug. 8, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today reported improved financial results with an operating loss of $1.7 million and operating income of $12.3 million for
Toggle Summary Akcea and Ionis Announce Submission of Marketing Authorization Application for Volanesorsen to the European Medicines Agency
CAMBRIDGE, Mass. and CARLSBAD, Calif. , July 27, 2017 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA) and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that a marketing authorization application (MAA) has been submitted to the European Medicines Agency (EMA) for volanesorsen
Toggle Summary Ionis Pharmaceuticals to Hold Second Quarter 2017 Financial Results Webcast
Webcast scheduled for Tuesday, August 8 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , July 25, 2017 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Tuesday, August 8 at 11:30 a.m. Eastern Time to discuss its second quarter 2017
Toggle Summary Akcea Therapeutics Announces Closing of Initial Public Offering
CAMBRIDGE, Mass. , July 19, 2017 /PRNewswire/ -- Akcea Therapeutics, Inc. today announced the closing of its initial public offering of 17,968,750 shares common stock at a public offering price of $8.00 per share, including 2,343,750 shares of common stock issued upon full exercise by the
Toggle Summary Ionis Earns $10 Million Milestone Payment from Biogen for Advancing a New Program in its Neurology Collaboration
CARLSBAD, Calif. , July 17, 2017 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has earned a $10 million milestone payment from Biogen associated with the validation of an undisclosed neurological disease target. Ionis and Biogen have a broad strategic
Toggle Summary Akcea Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass. , July 13, 2017 /PRNewswire/ -- Akcea Therapeutics, Inc. today announced the pricing of its initial public offering of 15,625,000 shares common stock at a public offering price of $8.00 per share, for gross proceeds of $125.0 million before underwriting discounts and commissions
Toggle Summary New Data Presented at Peripheral Nerve Society Meeting Further Support Potential Benefit of Inotersen
Significant benefit observed for both clinical measurements of neurological disease progression and quality of life at 8 and 15 months in patients with FAP CARLSBAD, Calif. , July 10, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) presented new top-line data from the Phase 3
Toggle Summary New Data Reaffirm Clinically Meaningful Benefit of SPINRAZA®(nusinersen) in Individuals with Spinal Muscular Atrophy Across Disease Severity
Toggle Summary Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington's Disease Completed and Open-Label Extension Study to Open in 2H 2017
Toggle Summary Akcea Therapeutics Launches Proposed Initial Public Offering
Toggle Summary SPINRAZA® (nusinersen) Approved in the European Union
Toggle Summary Akcea Announces Publication in The New England Journal of Medicine of Data with AKCEA-ANGPTL3-L Rx Showing Favorable Cardiometabolic Effects
Toggle Summary Ionis Pharmaceuticals Announces Phase 3 NEURO-TTR Study of Inotersen (IONIS-TTR Rx) Meets Both Primary Endpoints
Toggle Summary Ionis Pharmaceuticals Provides Corporate Update at 2017 Annual Meeting of Stockholders
Toggle Summary Ionis Pharmaceuticals to Present at Bank of America Merrill Lynch 2017 Healthcare Conference
Toggle Summary Akcea Therapeutics Announces Appointment of Edward Fitzgerald to Board of Directors
Toggle Summary Ionis Reports Financial Results and Highlights for First Quarter 2017
Toggle Summary Ionis Pharmaceuticals to Hold First Quarter 2017 Financial Results Webcast
Toggle Summary Final Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy
Toggle Summary Biogen’s SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
Toggle Summary Ionis Enters into Collaboration with Ribo to Advance RNA-Targeted Therapeutics in China
Toggle Summary Akcea Initiates Phase 2 Study of AKCEA-APO(a)-L Rx in Patients with High Lp(a) and Cardiovascular Disease
Toggle Summary Ionis Pharmaceuticals to Present at Needham Healthcare Conference
Toggle Summary Akcea Therapeutics Announces Three Additions to Board of Directors
Toggle Summary Akcea Therapeutics Files Registration Statement for Proposed Initial Public Offering
Toggle Summary Akcea and Ionis Announce Positive Results from Pivotal Study of Volanesorsen in Patients with Familial Chylomicronemia Syndrome (FCS)
Toggle Summary Ionis' 2016 Financial Results Outperform Financial Guidance
Toggle Summary Ionis and Akcea Close on Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx
Toggle Summary Ionis Pharmaceuticals to Hold 2016 Financial Results Conference Call
Toggle Summary Ionis Earns $75 Million from Bayer for Advancing IONIS-FXI Rx and IONIS-FXI-L Rx
Toggle Summary Ionis Earns $5 Million Milestone Payment from Biogen for Advancing a New Program Under Its Broad Neurology Strategic Collaboration
Toggle Summary Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
Toggle Summary New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy
Toggle Summary Ionis Pharmaceuticals Significantly Improves Upon 2016 Financial Guidance
Toggle Summary Ionis and Akcea Enter into Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx
Toggle Summary Ionis Pharmaceuticals Reports Positive Data from Phase 2 Study of IONIS-GCGR Rx in Patients with Type 2 Diabetes